Nanoformulated cannabidiol for skin disorders: A GRADE-based systematic review of therapeutic evidence and efficacy.

Cannabidiol (CBD), a non-psychoactive chemical derived from Cannabis sativa L., has significant dermatological potential due to its antiinflammatory, antioxidant, and wound healing attributes. However, its clinical usage is limited by instability, minimal skin penetration, and poor solubility. Nanotechnology-based delivery systems such as pickering emulsions, cryogels, lipid nanoparticles, and nanomicelles have emerged as promising strategies to enhance localized skin delivery, improve penetration, enable sustained release, and reduce adverse effects. According to this analysis of 16 papers and 18 patents (2019-2024), CBD that has been nanoformulated offers improved tolerability, sustained release, and skin delivery. According to GRADE review, impacts on dermal absorption, inflammation, and wound healing demonstrated intermediate certainty, but outcomes such as skin penetration, controlled release, and safety showed high certainty. Applications for acne, psoriasis, and eczema show enhanced patient compliance and efficacy. Despite clinical and regulatory obstacles, nano-CBD platforms provide a safe, focused, and efficient approach to improving dermatological care.